EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) Receives Consensus Rating of “Buy” from Brokerages

Shares of EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) have been given a consensus recommendation of “Buy” by the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company.

Several research analysts have recently commented on the company. Citigroup reissued a “buy” rating on shares of EssilorLuxottica in a report on Thursday, December 11th. Zacks Research cut shares of EssilorLuxottica from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Royal Bank Of Canada reissued an “outperform” rating on shares of EssilorLuxottica in a report on Tuesday, October 28th. UBS Group raised shares of EssilorLuxottica from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 27th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of EssilorLuxottica in a research report on Friday, December 5th.

EssilorLuxottica Stock Down 2.3%

Shares of OTCMKTS ESLOY opened at $159.00 on Monday. The stock’s 50-day simple moving average is $172.06 and its two-hundred day simple moving average is $160.82. EssilorLuxottica has a twelve month low of $118.60 and a twelve month high of $186.81. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.67 and a current ratio of 0.97.

About EssilorLuxottica

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.